Two separate class action lawsuitswere filed against ICN Pharmaceuticals Inc and its Viratek Inc&lt;VIRA> subsidiary, charging the companies with disseminatingallegedly false and misleading information regarding thecompany's drug Virazole, which is being tested as a possibletreatment for AIDS.    The suit, filed in Federal Court here on behalf of ICNshareholders, charges that disclosures made by ICN over aboutthe past year encouraged the investing public to believe thatVirazole was a promising drug of major importance and did notdisclose serious adverse side effects, court documents said.    An ICN spokesman declined comment on the lawsuits.Attorneys for the plaintiffs were not immediately available forcomment.    Virazole, also known as ribavirin, is undergoing extensivetesting as a possible treatment for AIDS-related illnesses.    The drug, which is available in a number of countriesoutside the United States, has been approved by the FDA for usedomestically in aerosol form as a treatment for an infectionthat strikes young children, called respiratory syncytialvirus.    The FDA and a house subcommittee are conducting their ownseparate probes into whether ICN withheld data from the FDA onadverse reactions to the antiviral drug.    The Securities and Exchange Commission is alsoinvestigating the company. Reuter&#3;